missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Adalimumab Chimeric Recombinant Mouse Monoclonal Antibody (D2E7 (Adalimumab))

Description
Binds to soluble TNF-alpha, but not to lymphotoxin (TNF beta).
Adalimumab (Humira) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab binds to the TNF alpha (tumor necrosis factor-alpha), and blocks its interaction with TNF alpha receptors, reducing the inflammatory response of autoimmune diseases.
Specifications
Specifications
| Antigen | Adalimumab Chimeric |
| Applications | ELISA, Inhibition Assays, Immunohistochemistry, Immunocytochemistry |
| Classification | Recombinant Monoclonal |
| Clone | D2E7 (Adalimumab) |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% ProClin 300 |
| Gene Alias | D2E7; Humira |
| Host Species | Mouse |
| Immunogen | This antibody was generated by affinity maturation from the 2SD4 scFv, which in turn was selected on human TNF alpha by guided phage-display technology, using the murine anti-hTNF alpha antibody Mab32 as a template. |
| Show More |